Cansinobio's 24-Valent Pneumococcal Vaccine Enters Phase I/II Trial, Completes First Enrollment on May 25

GateNews
According to an announcement on May 25, Cansinobio's 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) has officially launched Phase I/II clinical trials with the completion of the first subject enrollment. The vaccine targets major circulating pneumococcal serotypes using a dual-carrier technology platform and is designed for administration in individuals aged 2 months and above. No comparable products have been commercialized domestically or internationally to date.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments